Merck Reveals Study Success, and Possible Safety Worries, for Eye Drug Hopeful

Merck remigromig DME trial results raise safety concerns

Remigromig matched a standard treatment for diabetic macular edema in a late-stage study, but showed higher rates of certain retinal complications

Wnt drug gives MSD first eye disease win after EyeBio deal

MSD's return to the ophthalmology field has been charged up with a positive phase 3 trial of Wnt-targeted remigromig in diabetic macular oedema.

Remigromig: Drug for diabetes-related eye disease meets trial goal

Remigromig activates a cell growth-regulating system called the Wnt pathway to ​help repair the retina's leaky blood...

Merck's drug for diabetes-related eye disease meets trial goal

Merck said on Thursday its injectable drug for a serious eye disease affecting people with diabetes ​was as effective as the current standard treatment in improving visual ‌sharpness in a clinical trial.

Merck reveals study success, and possible safety worries, for eye drug hopeful

A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate among analysts.   

Merck sees pivotal victory for $3B eye disease prospect

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.